AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2810454 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study 2810454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30628552 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy activities (12 artistic activities)
Number of subjects: 55
Study 30628552 — intervention group
Group type: COMPARATOR
Intervention: Ordinary activities
Number of subjects: 55
Study 28125513 — intervention group
Group type: EXPERIMENTAL
Intervention: DC vaccine
Number of subjects: 40
Study 28125513 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 25753493 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of alpha-lipoic acid (ALA) supplementation for 12 weeks
Number of subjects: 58
Study 23877706 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir monotherapy
Number of subjects: 88
Study 23877706 — intervention group
Group type: COMPARATOR
Intervention: Faldaprevir-PegIFN-RBV triple therapy
Number of subjects: 88
Study 21883124 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 1.5 μg
Number of subjects: 52
Study 21883124 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 5 μg
Number of subjects: 52
Study 21883124 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 15 μg
Number of subjects: 52
Study 21883124 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 52
Study 19787539 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus of attention (focusing on surroundings)
Number of subjects: 0
Study 19787539 — intervention group
Group type: COMPARATOR
Intervention: Internal focus of attention (focusing on running movement and breathing)
Number of subjects: 0
Study 17940987 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA therapy (150 mg oral daily for 40 days)
Number of subjects: 30
Study 17940987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14704629 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrolife
Number of subjects: 176
Study 14704629 — intervention group
Group type: COMPARATOR
Intervention: MediCult
Number of subjects: 176
Study 14704629 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrolife (ICSI cycles)
Number of subjects: 176
Study 11171607 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 9
Study 11171607 — intervention group
Group type: COMPARATOR
Intervention: Protein-free fast
Number of subjects: 9
Study 9762002 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg/day of hGH for 7 days
Number of subjects: 16
Study 9762002 — intervention group
Group type: COMPARATOR
Intervention: Combined lower dose group (0.05 or 0.1 IU/kg/day of hGH for 7 days)
Number of subjects: 16
Study 7852551 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with ganciclovir for 2 weeks and then high-dose acyclovir for 2.5 months
Number of subjects: 3552
Study 7852551 — intervention group
Group type: COMPARATOR
Intervention: High-dose acyclovir alone for 3 months
Number of subjects: 3552
Study 7852551 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic CMV infections
Number of subjects: 3552
Study 7852551 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic CMV infections
Number of subjects: 3552
Study 2691482 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxycillin/clavulanate
Number of subjects: 141
Study 2691482 — intervention group
Group type: COMPARATOR
Intervention: cefoxitin
Number of subjects: 141
Study 1183220 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon
Number of subjects: 26
Study 1183220 — intervention group
Group type: COMPARATOR
Intervention: Placebo (antacid containing)
Number of subjects: 26
Study 31838759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 344
Study 31240310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and/or Trastuzumab
Number of subjects: 8381
Study 27981455 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual walking integrated physiotherapy
Number of subjects: 44
Study 27981455 — intervention group
Group type: COMPARATOR
Intervention: Traditional physiotherapy (control group)
Number of subjects: 44
Study 25617251 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered foster care (FCG)
Number of subjects: 117
Study 25617251 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual group (CAUG)
Number of subjects: 117
Study 25617251 — intervention group
Group type: COMPARATOR
Intervention: Never-Institutionalized group (NIG)
Number of subjects: 117
Study 24200413 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal fusion (instrumented or noninstrumented fusion, stabilization)
Number of subjects: 473
Study 24200413 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary cognitive-behavioral and exercise rehabilitation
Number of subjects: 473
Study 21532506 — intervention group
Group type: EXPERIMENTAL
Intervention: C/P/T (Carboplatin and Paclitaxel plus Talactoferrin)
Number of subjects: 110
Study 21532506 — intervention group
Group type: COMPARATOR
Intervention: C/P/P (Carboplatin and Paclitaxel plus Placebo)
Number of subjects: 110
Study 18165598 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine + rofecoxib 50 mg
Number of subjects: 114
Study 18165598 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine + placebo
Number of subjects: 114
Study 18165598 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine + placebo
Number of subjects: 114
Study 18165598 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine + rofecoxib 50 mg
Number of subjects: 114
Study 16861092 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl effervescent buccal tablet (FEBT) 100 microg
Number of subjects: 32
Study 16861092 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl effervescent buccal tablet (FEBT) 200 microg
Number of subjects: 32
Study 16861092 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl effervescent buccal tablet (FEBT) 400 microg
Number of subjects: 32
Study 16861092 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl effervescent buccal tablet (FEBT) 800 microg
Number of subjects: 32
Study 15733521 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosmotic polyethylene glycol 3350 electrolyte solution
Number of subjects: 12
Study 15733521 — intervention group
Group type: COMPARATOR
Intervention: Isosmotic electrolyte solution
Number of subjects: 12
Study 12928729 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway (path group)
Number of subjects: 87
Study 12928729 — intervention group
Group type: COMPARATOR
Intervention: Traditional practice (control group)
Number of subjects: 87
Study 10362377 — intervention group
Group type: COMPARATOR
Intervention: Platelet aggregability studies on day 1 after pacemaker implantation
Number of subjects: 20
Study 10362377 — intervention group
Group type: COMPARATOR
Intervention: Platelet aggregability studies on day 3 after pacemaker implantation
Number of subjects: 20
Study 10362377 — intervention group
Group type: COMPARATOR
Intervention: Platelet aggregability studies on day 30 after pacemaker implantation
Number of subjects: 20
Study 7745051 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 3 post-insemination
Number of subjects: 1228
Study 7745051 — intervention group
Group type: COMPARATOR
Intervention: Embryo transfer on day 2 post-insemination
Number of subjects: 1228
Study 2292629 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress inoculation program
Number of subjects: 72
Study 2292629 — intervention group
Group type: COMPARATOR
Intervention: Child-focused intervention program
Number of subjects: 72
Study 7288563 — intervention group
Group type: EXPERIMENTAL
Intervention: Misattribution treatment (high-frequency noise)
Number of subjects: 0
Study 7288563 — intervention group
Group type: COMPARATOR
Intervention: Control group (shy women expecting shyness-irrelevant side effects)
Number of subjects: 0
Study 7288563 — intervention group
Group type: COMPARATOR
Intervention: Control group (not-shy women)
Number of subjects: 0
Study 31744705 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 30
Study 31744705 — intervention group
Group type: EXPERIMENTAL
Intervention: AuraGain
Number of subjects: 30
Study 31744705 — intervention group
Group type: EXPERIMENTAL
Intervention: iLTS-D
Number of subjects: 30
Study 28763243 — intervention group
Group type: EXPERIMENTAL
Intervention: FS MDPI 50/12.5 mcg
Number of subjects: 640
Study 28763243 — intervention group
Group type: EXPERIMENTAL
Intervention: FS MDPI 100/12.5 mcg
Number of subjects: 640
Study 28763243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fp MDPI 50 mcg
Number of subjects: 640
Study 28763243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fp MDPI 100 mcg
Number of subjects: 640
Study 28763243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study 28850523 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 34
Study 28850523 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 34
Study 24977321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided ureteroscopy
Number of subjects: 50
Study 24977321 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic guided ureteroscopy
Number of subjects: 50
Study 22017530 — intervention group
Group type: EXPERIMENTAL
Intervention: Y1 antagonist (AR-H040922) during atenolol
Number of subjects: 71
Study 22017530 — intervention group
Group type: EXPERIMENTAL
Intervention: Y1 antagonist (AR-H040922) during metoprolol
Number of subjects: 71
Study 22017530 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 71
Study 22017530 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 71
Study 22017530 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase (metoprolol)
Number of subjects: 71
Study 22017530 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase (atenolol)
Number of subjects: 71
Study 21111318 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-forced infusion (air pump)
Number of subjects: 0
Study 21111318 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gas-forced infusion)
Number of subjects: 0
Study 21111318 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 19014792 — intervention group
Group type: EXPERIMENTAL
Intervention: PATH Woman's Condom (WC)
Number of subjects: 75
Study 19014792 — intervention group
Group type: COMPARATOR
Intervention: FC1 Female Condom (FC1)
Number of subjects: 75
Study 16802774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 200 microg daily
Number of subjects: 736
Study 16802774 — intervention group
Group type: COMPARATOR
Intervention: Montelukast, 10 mg daily
Number of subjects: 736
Study 12706276 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion with warmed normal saline
Number of subjects: 160
Study 12706276 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amnioinfusion)
Number of subjects: 160
Study 12594897 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylaminopenicillin-based therapy
Number of subjects: 110
Study 12594897 — intervention group
Group type: COMPARATOR
Intervention: Cephalosporin-based antibiotic therapy
Number of subjects: 110
Study 8722604 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate with erythromycin
Number of subjects: 12
Study 8722604 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin without zinc acetate
Number of subjects: 12
Study 1571637 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy
Number of subjects: 33
Study 1571637 — intervention group
Group type: COMPARATOR
Intervention: Control procedures (herniorrhaphy and testicular exploration)
Number of subjects: 33
Study 6536768 — intervention group
Group type: EXPERIMENTAL
Intervention: Grief group therapy
Number of subjects: 0
Study 6536768 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30521663 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mediated approach and speech-generating device
Number of subjects: 45
Study 30521663 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual condition with untrained peers
Number of subjects: 45
Study 30420116 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV-PV (Lot A, B, C)
Number of subjects: 1500
Study 30420116 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV-PV
Number of subjects: 1500
Study 30420116 — intervention group
Group type: COMPARATOR
Intervention: Rotarix®
Number of subjects: 1500
Study 30420116 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV-PV, Rotarix®
Number of subjects: 1500
Study 26948468 — intervention group
Group type: COMPARATOR
Intervention: Physical activity intervention (brisk walking)
Number of subjects: 0
Study 26948468 — intervention group
Group type: COMPARATOR
Intervention: Nutritional intervention (lycopene supplementation or increased fruit and vegetables with reduced dairy consumption)
Number of subjects: 0
Study 24762259 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (6-months treatment)
Number of subjects: 60
Study 22534580 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined non-consensual kiss from a physically dirty man
Number of subjects: 140
Study 22534580 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined consensual kiss from a physically clean man
Number of subjects: 140
Study 22534580 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined consensual kiss from a physically dirty man
Number of subjects: 140
Study 22534580 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagined non-consensual kiss from a physically clean man
Number of subjects: 140
Study 20925996 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal contraceptive counselling
Number of subjects: 180
Study 20925996 — intervention group
Group type: COMPARATOR
Intervention: Educational leaflet (Control)
Number of subjects: 180
Study 17949786 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 39
Study 17949786 — intervention group
Group type: EXPERIMENTAL
Intervention: False-positive cases (CD3(+) and CD5(+) T cells)
Number of subjects: 39
Study 17949786 — intervention group
Group type: COMPARATOR
Intervention: Negative post-rituximab bone marrow
Number of subjects: 39
Study 16097553 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA with relatively flat or concave tibial insert (retaining posterior cruciate ligament)
Number of subjects: 39
Study 16097553 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA with concave or posterior-stabilized tibial component (resecting posterior cruciate ligament)
Number of subjects: 39
Study 16097553 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study 12794096 — intervention group
Group type: COMPARATOR
Intervention: Walking at 0.5-1.5 m/s with loads of 0, 10, 20, and 30% body mass
Number of subjects: 8
Study 12794096 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at speeds of 1.5-2.0 m/s
Number of subjects: 8
Study 12794096 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of generating force per unit volume of active muscle (k) across all conditions
Number of subjects: 8
Study 10852048 — intervention group
Group type: EXPERIMENTAL
Intervention: New concentrated inactivated leptospirosis vaccine (0.5 ml, single injection)
Number of subjects: 0
Study 10852048 — intervention group
Group type: COMPARATOR
Intervention: Existing commercial vaccine (2.0 ml and 2.5 ml, two injections)
Number of subjects: 0
Study 7491373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 89
Study 7491373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 1710591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl-starch (250 ml daily) + Pentoxifylline (oral: 1200 mg/day; i.v.: 300 mg/day)
Number of subjects: 40
Study 1710591 — intervention group
Group type: COMPARATOR
Intervention: Control (no hemodilution or rheological therapy)
Number of subjects: 40
Study 1710591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl-starch + Pentoxifylline
Number of subjects: 40
Study 6955502 — intervention group
Group type: EXPERIMENTAL
Intervention: Butler waxed dental floss
Number of subjects: 80
Study 6955502 — intervention group
Group type: EXPERIMENTAL
Intervention: Butler unwaxed dental floss
Number of subjects: 80
Study 6955502 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson and Johnson waxed dental floss
Number of subjects: 80
Study 6955502 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson and Johnson unwaxed dental floss
Number of subjects: 80
Study 30292760 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 0
Study 30292760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30292760 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study 29155035 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL 0.25% bupivacaine (treatment group)
Number of subjects: 84
Study 29155035 — intervention group
Group type: COMPARATOR
Intervention: 20 mL normal saline solution (control group)
Number of subjects: 84
Study 27267310 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized, body‐worn hand hygiene system
Number of subjects: 3256
Study 27267310 — intervention group
Group type: COMPARATOR
Intervention: Usual intraoperative hand hygiene (control)
Number of subjects: 3256
Study 24603631 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized frequency whole body vibration (WBV) for three 4-minute sessions
Number of subjects: 18
Study 23102189 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol 250/10 μg twice daily
Number of subjects: 279
Study 23102189 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol 400/12 μg twice daily
Number of subjects: 279
Study 20838819 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 13
Study 20838819 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-Lateral Decubitus position
Number of subjects: 13
Study 20838819 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-Lateral Decubitus position
Number of subjects: 13
Study 20838819 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 13
Study 20838819 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 13
Study 17947725 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 430
Study 17947725 — intervention group
Group type: EXPERIMENTAL
Intervention: mIFL
Number of subjects: 430
Study 17947725 — intervention group
Group type: EXPERIMENTAL
Intervention: CapeIRI
Number of subjects: 430
Study 17947725 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI+Bev
Number of subjects: 430
Study 17947725 — intervention group
Group type: EXPERIMENTAL
Intervention: mIFL+Bev
Number of subjects: 430
Study 16118599 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole/nystatin ovules
Number of subjects: 0
Study 16118599 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole gel
Number of subjects: 0
Study 12120776 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot Carbides (RC)
Number of subjects: 32
Study 12120776 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-Snap system (SS)
Number of subjects: 32
Study 12120776 — intervention group
Group type: EXPERIMENTAL
Intervention: OneGloss (OG)
Number of subjects: 32
Study 12120776 — intervention group
Group type: EXPERIMENTAL
Intervention: CompoSite Points (CS)
Number of subjects: 32
Study 12120776 — intervention group
Group type: COMPARATOR
Intervention: Fuji II LC
Number of subjects: 32
Study 12120776 — intervention group
Group type: COMPARATOR
Intervention: Photac-Fil Quick (ESPE)
Number of subjects: 32
Study 10320241 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (HCCs)
Number of subjects: 886
Study 10320241 — intervention group
Group type: COMPARATOR
Intervention: Conventional circuits (control group)
Number of subjects: 886
Study 8729093 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) supplementation
Number of subjects: 49
Study 8729093 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (FOC) supplementation
Number of subjects: 49
Study 8729093 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) supplementation
Number of subjects: 49
Study 8729093 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO) placebo
Number of subjects: 49
Study 1679626 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed treatment condition (shorter intersession intervals)
Number of subjects: 0
Study 1679626 — intervention group
Group type: COMPARATOR
Intervention: Spaced treatment condition (longer intersession intervals)
Number of subjects: 0
Study 1679626 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance between behavioural, cognitive, and physiological anxiety responses
Number of subjects: 0
Study 6627195 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert behavior rehearsal in a relaxed condition
Number of subjects: 33
Study 6627195 — intervention group
Group type: COMPARATOR
Intervention: Relaxation only
Number of subjects: 33
Study 6627195 — intervention group
Group type: COMPARATOR
Intervention: No preparation at all
Number of subjects: 33
Study 30882234 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 188
Study 30882234 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study 29693310 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 692
Study 29693310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 692
Study 29693310 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet with baseline methylation at cg26663590
Number of subjects: 692
Study 29693310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet with baseline methylation at cg26663590
Number of subjects: 692
Study 28128751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 20
Study 28128751 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution (NaCl)
Number of subjects: 20
Study 24582547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sat Pad with STIR
Number of subjects: 25
Study 24582547 — intervention group
Group type: COMPARATOR
Intervention: DWI using STIR
Number of subjects: 25